Human anti-human mcp-1 antibody and fragment of said antibody
CA 2497804 A1 · Owner: Nakashima, Toshihiro · Inventors: Nishihara, Tsukasa; Sugimura, Kazuhisa; Nakashima, Toshihiro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It is intended to provide substances efficacious in treating immunopathies in which MCP-1 participates. Using the phage antibody method scFv having a high , affinity for human MCP-1 is obtained. Based on the data concerning the VH chain and the VL chain obtained from this scFv a human antihuman MCP-1 , antibody and a human antihuman MCP-1 antibody fragment are obtained. These antibody and antibody fragment are expected as usable as remedies for inflammation and immunopathies caused by MCP-1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 10, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 10, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 10, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.